District Court in Delaware invalidates four Ampyra patents
“We are disappointed by the court’s decision and are preparing our appeal,” Dr. Ron Cohen, Acorda's president and CEO, said in a press release. “Medical innovation depends on the recognition of valid intellectual property claims. We believe that we demonstrated novel and unexpected findings in our AMPYRA development program that led to the issuance of valid patents.”
Though Acorda Therapeutics is appealing the case, it is also working on contingency plans in the event that the company loses Ampyra exclusivity. This plan would address Acorda Therapeutics’ business needs and objectives. The company noted in its press release that it will provide an update after finalizing a timeline for implementing the plans.
Acorda Therapeutics, a biotechnology company founded in 1995, develops therapies to restore function and improve the lives of patients suffering from neurological disorders.